Form 4 for SLXN Silexion Therapeutics Corp
Accepted 2025-12-31 00:00:00 ET · period of report 2025-02-09 · accession 0001178913-25-004145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-12-31 | 2025-02-09 | SLXN | Lushi Avner | Dir | A - Grant | $0.00 | +1,587 | 1,587 | New | $0 |
| DI | 2025-12-31 | 2025-02-09 | SLXN | Lushi Avner | Dir | A - Grant | $0.00 | +1,872 | 1,872 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-02-09 | A | A | 1,587 | $0.00 | 1,587 | I By Guangzhou Sino-Israel Biotech Fund | — | — | (F1) Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer for director services provided by the Reporting Person and Shlomo Noy. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Dr. Noy's (each, with respect to half of the shares) continued service through such date. (F2) The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. (F3) The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. |
| 2 | Derivative | Stock Option (right to buy ordinary shares) | 2025-02-09 | A | A | 1,872 | $0.00 | 1,872 | I By Guangzhou Sino-Israel Biotech Fund | $18.90 · 2026-02-09 to 2035-02-09 | 1,872 Ordinary Shares | (F7) The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. (F6) Represents stock options granted by the Issuer to GIBF for director services provided by the Reporting Person and Shlomo Noy (each, with respect to half of the options). (F3) The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. (F8) All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's or Dr. Noy's (each, with respect to half of the options) continued service through such date. |